Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in Turkey / NCT07268859
Recruiting Not applicable

Effect of Fan Application in Preventing Ticagrelor-Associated Dyspnea

NCT07268859 · tracked via the Priya Life Science Turkey tracker
Sponsor
Acibadem University
Phase
Not applicable
Started
2025-03-15
Last updated
2025-12-08

Condition(s) studied

Acute Coronary SyndromesTicagrelorDyspnea

Investigational drug(s) / intervention(s)

STANDART CARESTANDART CARE & FAN THERAPY

STANDART CARE: Routine ward care including semi-Fowler position and breathing exercises. Standard institutional care will be applied. Presence, number, and severity of dyspnea attacks will be recorded during the first 2 hours after ticagrelor administration.

STANDART CARE & FAN THERAPY: In addition to standard care, patients will undergo hand fanning for 5 minutes at 30, 60, and 120 minutes after ticagrelor administration. The fan will be directed toward the patient's face from a distance of \~15 cm. Dyspnea severity and number of episodes will be recorded during this period.

Study summary

This study will be conducted in the coronary intensive care unit of Dr. Siyami Ersek Chest, Heart and Vascular Surgery Training and Research Hospital. It aims to investigate the effect of hand fan therapy on ticagrelor-associated dyspnea in patients receiving ticagrelor.

Eligibility

Sex
ALL
Min age
18 Years
Max age
65 Years
Healthy volunteers
Accepted
Inclusion Criteria: * Between the ages of 18 and 65, * No severe hearing and vision problems, * Can speak and understand Turkish, * Easy to communicate with, * First-time sufferer of acute coronary syndrome (ACS) for the first time, * Decided to start ticagrelor therapy, * Able to adapt to treatment, * Individuals who volunteered to participate in the research. Exclusion Criteria: * Having any problem that prevents you from communicating cognitively, emotionally and verbally, * Obstructive sleep abnormalities, * Have a disease that affects respiratory function (stage IV cancer, bronchial asthma, COVID-19, lung cancer, pulmonary edema, chronic obstructive pulmonary disease, pulmonary hypertension, pulmonary embolism, pneumonia or bronchitis, etc.), * With metabolic abnormalities, * Intubated after the procedure, * Previously treated with ticagrelor, * Individuals who did not volunteer to participate in the study. Losses to follow up * Individuals who wish to leave the study voluntarily. * Saturation value below 95%, * The one with the arrest, * Who will not be able to fulfill the requirements of the work, * Individuals with life-threatening conditions

Primary outcome measure(s)

  • Incidence of ticagrelor-associated dyspnea — Time Frame: 0-120 minutes after ticagrelor administration (T1: baseline; T2: 30 min; T3: 60 min; T4: 120 min) Unit of Measure: Percentage of participants (%)
    The proportion of participants who experience dyspnea within 120 minutes following ticagrelor administration will be recorded.

Trial sites (2)

FacilityCityRegionStatus
İstanbul Üniversitesi-Cerrahapaşa Istanbul Avcılar Not Yet Recruiting
Sağlık Bilimleri Üniversitesi Dr. Siyami Ersek Göğüs Kalp ve Damar Cerrahisi Eğitim Araştırma Hastanesi Istanbul Üsküdar Recruiting

More Acibadem University trials in Turkey

"Turkish Validity and Reliability of the Heat Sensitivity Scale for Individuals With Parkinson's Disease" Recruiting
The Effect of Touch Methods on Pain and Physiological Parameters in Preterm Infants During Endotracheal Aspiration Recruiting
Investigation of Walking Training With Different Slope Types in COPD Patients Recruiting
Comorbidity, Cognition, Gait Speed, and Respiratory Muscle Strength in Older Adults Enrolling by invitation
Turkish Cognitive Self-Efficacy Questionnaire in Parkinson's Disease Recruiting

Other trials for the same condition

Breathing Exercises for Dyspnea and Anxiety in Heart Failure Active, not recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07268859 on ClinicalTrials.gov ↗ ← All trials in Turkey